Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.68 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.59 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.55 |
| ▸ | NPY1R | P25929 | 3/20 | 0.55 |
| ▸ | NPY4R | P50391 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450082 | 0.95 | TFPI (0.60) | TFPINMUR2NMUR1NPY5RNPY1R | |
| SCHEMBL6437697 | 0.90 | TFPI (0.63) | TFPINMUR2NMUR1 | |
| SCHEMBL6437703 | 0.90 | TFPI (0.63) | TFPINMUR2NMUR1 | |
| SCHEMBL29746571 | 0.90 | TFPI (0.60) | TFPINMUR2NMUR1 | |
| SCHEMBL30553847 | 0.90 | TFPI (0.58) | TFPINMUR2NMUR1NPY5RNPY1R | |
| SCHEMBL30432497 | 0.88 | TFPI (0.70) | TFPINMUR2NMUR1NPY5RNPY1R | |
| SCHEMBL31141451 | 0.88 | TFPI (0.65) | TFPINPY5RNPY1RNPY4R | |
| SCHEMBL29746772 | 0.88 | KISS1R (0.60) | TFPINMUR2NMUR1NPY5RNPY1R | |
| SCHEMBL31519352 | 0.86 | NPY4R (0.61) | TFPINPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL30880895 | 0.86 | OPRM1 (0.60) | TFPINPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099725-A1 | PHARMACEUTICAL PREPARATION CONTAINING A MIXTURE OF A NATRIURETIC PEPTIDE (ANP) AND A PEPTIDIC INHIBITOR OF THE CXCR4 RECEPTOR | PHARIS BIOTEC GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |